20 Large-Cap Stocks Insiders and Short Sellers Are Dumping Like Crazy

Page 10 of 18

9. Insmed Incorporated (NASDAQ:INSM)

Short Float: 8.51%

Insider Transaction: -15.14%

Insmed Incorporated (NASDAQ:INSM) is a biopharmaceutical firm located in New Jersey. The company focuses on developing therapies for serious and rare diseases, including respiratory and inflammatory conditions. Its flagship product, Arikayce, targets treatment-refractory Mycobacterium avium complex lung disease. The company competes with market players like Horizon and Vertex Pharmaceuticals through targeted innovation and global regulatory expansion. It has consistently invested in novel therapeutics, thus enhancing the treatment paradigms across multiple underserved medical domains.

Insmed Incorporated (NASDAQ:INSM) has been expecting revenue from brensocatib but has rescheduled it to the third quarter of 2025 because of approval delays. The outflow of cash in 2024 stands at $191 million in Q4, including the investments made towards brensocatib. This cash burn is higher than any of the previous quarters, and hence, concerns have started to rise regarding the company’s financial stability. Additionally, Insmed Incorporated (NASDAQ:INSM) may require future financing since it uses its net income for funding and must continue investing in its pipeline.

Insmed Incorporated (NASDAQ:INSM) has a short float of 8.51%, putting the company under consistent pressure from bearish positions. Additionally, the steep 15.14% drop in insider ownership raises red flags about confidence in the company’s long-term pipeline and, thus, turning it into a large-cap stock abandoned by insiders and short sellers.

Page 10 of 18